Yuan Da Pharmaceuticals (00512): The application to include the global innovative radiopharmaceutical TLX591 in the international multicenter Phase III clinical trial has received implicit approval from the China National Medical Products Administration.

Zhtng Cijng APP News, Evergrande Pharma (00512) announced that their global innovative investigational radiopharmaceutical agent for the treatment of prostate cancer, TLX591 (177Lu-rosopatamab tetraxetan), has been included in the application for an international multicenter Phase III clinical trial. Recently, it has received an implied approval from the National Medical Products Administration of the People's Republic of China (NMPA). This marks an important research and development advancement for the group in the field of nuclear medicine for anti-tumor diagnosis and treatment. The group attaches great importance to the globalization development strategy of the nuclear medicine industry, actively promoting the global development and registration process of innovative nuclear medicine products, and will continue to deepen the global expansion of the group's nuclear medicine product pipeline.